Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Combination Treatment with Imetelstat, a Telomerase Inhibitor, and Ruxolitinib Depletes Myelofibrosis Hematopoietic Stem Cells and Progenitor Cells

Cing Siang Hu, Fei Huang, Ronald Hoffman, MD, Xiaoli Wang, MD PhD

Blood (2019) 134 (Supplement_1): 2963.

https://doi.org/10.1182/blood-2019-126189

Published: 2019

Journal Articles

The Genetic Architecture of Myeloproliferative Neoplasms-Blast Phase (MPN-BP) Stem Cells

Xiaoli Wang, MD PhD, Raajit K. Rampal, MD PhD, Cing Siang Hu, Noushin Farnoud, PhD, Christopher Famulare, MS, Minal A Patel, MPH, Erin McGovern, BA, Ronald Hoffman, MD

Blood (2019) 134 (Supplement_1): 1677.

https://doi.org/10.1182/blood-2019-128836

Published: 2019

Journal Articles

Specific and Recurrent Cytogenomic Abnormalities Originate in the Spleens of Myelofibrosis Patients and Contribute to Clonal Diversity and Disease Progression

Vesna Najfeld, PhD, Joseph Tripodi, MS, Xiaoli Wang, MD PhD, Myron Schwartz, MD, Marina Kremyanskaya, MDPhD, Edward Cytryn, Sharon Zirkiev, Raajit K. Rampal, MD, PhD, John O Mascarenhas, MD MS, Ronald Hoffman, MD

Blood (2014) 124 (21): 1871.

https://doi.org/10.1182/blood.V124.21.1871.1871

Published: 2014

Journal Articles

JAK2 Inhibitors Do Not Affect Stem Cells Present in the Spleens of Patients with Myelofibrosis

Xiaoli Wang, MD, PhD, Joseph Tripodi, MS, Jesse Novak, Min Lu, PhD., Yan Li, Vesna Najfeld, Ph.D, Ronald Hoffman, MD

Blood (2012) 120 (21): 1752.

https://doi.org/10.1182/blood.V120.21.1752.1752

Published: 2012

Journal Articles

Combination Treatment with RG7112 and Pegylated Interferon α 2a Specifically Targets JAK2V617F Positive Progenitor Cells From Patients with Myeloproliferative Neoplasms.

Min Lu, PhD., Xiaoli Wang, MD, PhD, Goar Mosoyan, Yan Li, Ronald Hoffman, MD

Blood (2012) 120 (21): 2865.

https://doi.org/10.1182/blood.V120.21.2865.2865

Published: 2012

Journal Articles

Characterization of Splenic CD34 + Cells From Patients with Primary Myelofibrosis

Xiaoli Wang, MD, PhD, Sonam Prakash, Min Lu, PhD, Yan Li, Attilio Orazi, MD, Ronald Hoffman, MD

Blood (2011) 118 (21): 2810.

https://doi.org/10.1182/blood.V118.21.2810.2810

Published: 2011

Journal Articles

Treatment with Nutlin-3, a Small-Molecule Antagonist of MDM2, in Combination with Low Doses of Pegylated Interferon Alpha 2a Targets Hematopoietic Progenitor Cells From Polycythemia Vera (PV) Patients

Min Lu, PhD, Joseph Tripodi, MS, Yan Li, Xiaoli Wang, MD, PhD, Vesna Najfeld, PhD, John Mascarenhas, MD, Ronald Hoffman, MD

Blood (2011) 118 (21): 796.

https://doi.org/10.1182/blood.V118.21.796.796

Published: 2011

Journal Articles

Treatment in Vitro with a Combination of Bcl-Xl Inhibitor-ABT-737 and a JAK2 Inhibitor Selectively Eliminates JAK2V617F MPN Progenitor Cells.

Min Lu, PhD, Wei Zhang, Jiapeng Wang, Yan Li, Xiaoli Wang, MD, PhD, Daniel Yoo, Adam Austin, John Mascarenhas, MD, Zhizhuang Joe Zhao, Ronald Hoffman, MD, Mingjiang Xu, MD, PhD

Blood (2009) 114 (22): 752.

https://doi.org/10.1182/blood.V114.22.752.752

Published: 2009

Journal Articles

Treatment with Pegylated Interferon Alpha 2a in Combination with the Bcl-Xl Inhibitor ABT-737 Specifically Targets JAK2V617F Positive Hematopoietic Progenitor Cells From Patients with Polycythemia Vera.

Min Lu, PhD, Wei Zhang, Daniel Yoo, Dmitriy Berenzon, Yan Li, Xiaoli Wang, MD, PhD, Adam Austin, John Mascarenhas, MD, Mingjiang Xu, MD, PhD, Ronald Hoffman, MD

Blood (2009) 114 (22): 3916.

https://doi.org/10.1182/blood.V114.22.3916.3916

Published: 2009

Journal Articles

Sequential Treatment of CD34 + Cells From Patients with Primary Myelofibrosis with Chromatin Modifying Agents Alters the Behavior of JAK2V617F Positive NOD/SCID Marrow Repopulating Cells.

Xiaoli Wang, MD, PhD, Wei Zhang, Adam Austin, Daniel Yoo, Min Lu, Mingjiang Xu, MD, PhD, Ronald Hoffman, MD

Blood (2009) 114 (22): 1910.

https://doi.org/10.1182/blood.V114.22.1910.1910

Published: 2009

Journal Articles

A Phase I Study of LBH589, a Novel Histone Deacetylase Inhibitor in Patients with Primary Myelofibrosis (PMF) and Post-Polycythemia/Essential Thrombocythemia Myelofibrosis (Post-PV/ET MF).

John Mascarenhas, MD, Xiaoli Wang, MD, PhD, Amelyn Rodriguez, BSN, RN, OCN, Mingjiang Xu, MD, PhD, Elaine Gorman, ANP-BC, Wenyong Zhang, MD, PhD, Judith D. Goldberg, Sc.D., Vesna Najfeld, Ph.D., Ronald Hoffman, MD

Blood (2009) 114 (22): 308.

https://doi.org/10.1182/blood.V114.22.308.308

Published: 2009

Journal Articles

Correction of the Abnormal Trafficking of Primary Myelofibrosis CD34 + Cells by Treatment with Chromatin Modifying Agents

Xiaoli Wang, MD, PhD, Wei Zhang, Takefumi Ishii, Selcuk Sozer, Jiapeng Wang, Mingjiang Xu, Ronald Hoffman, MD

Blood (2008) 112 (11): 101.

https://doi.org/10.1182/blood.V112.11.101.101

Published: 2008

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Combination Treatment with Imetelstat, a Telomerase Inhibitor, and Ruxolitinib Depletes Myelofibrosis Hematopoietic Stem Cells and Progenitor Cells

The Genetic Architecture of Myeloproliferative Neoplasms-Blast Phase (MPN-BP) Stem Cells

Specific and Recurrent Cytogenomic Abnormalities Originate in the Spleens of Myelofibrosis Patients and Contribute to Clonal Diversity and Disease Progression

JAK2 Inhibitors Do Not Affect Stem Cells Present in the Spleens of Patients with Myelofibrosis

Combination Treatment with RG7112 and Pegylated Interferon α 2a Specifically Targets JAK2V617F Positive Progenitor Cells From Patients with Myeloproliferative Neoplasms.

Characterization of Splenic CD34 + Cells From Patients with Primary Myelofibrosis

Treatment with Nutlin-3, a Small-Molecule Antagonist of MDM2, in Combination with Low Doses of Pegylated Interferon Alpha 2a Targets Hematopoietic Progenitor Cells From Polycythemia Vera (PV) Patients

Treatment in Vitro with a Combination of Bcl-Xl Inhibitor-ABT-737 and a JAK2 Inhibitor Selectively Eliminates JAK2V617F MPN Progenitor Cells.

Treatment with Pegylated Interferon Alpha 2a in Combination with the Bcl-Xl Inhibitor ABT-737 Specifically Targets JAK2V617F Positive Hematopoietic Progenitor Cells From Patients with Polycythemia Vera.

Sequential Treatment of CD34 + Cells From Patients with Primary Myelofibrosis with Chromatin Modifying Agents Alters the Behavior of JAK2V617F Positive NOD/SCID Marrow Repopulating Cells.

A Phase I Study of LBH589, a Novel Histone Deacetylase Inhibitor in Patients with Primary Myelofibrosis (PMF) and Post-Polycythemia/Essential Thrombocythemia Myelofibrosis (Post-PV/ET MF).

Correction of the Abnormal Trafficking of Primary Myelofibrosis CD34 + Cells by Treatment with Chromatin Modifying Agents

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only